Drugs / YN001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07309042 | Dec 2025 → Mar 2026 | atherosclerotic cardiovascular disease, cerebrovascular disorder | Beijing Inno Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07190885 | Nov 2025 → Sep 2026 | — | Beijing Inno Medicine Co., Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT05635084 | Dec 2022 → Aug 2024 | cardiovascular disorder | Beijing Inno Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06048588 | Oct 2023 → Apr 2025 | atherosclerotic cardiovascular disease | Beijing Inno Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07521007 | Jul 2026 → Jul 2027 expected | atherosclerosis, coronary artery disorder | Beijing Inno Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06700720 | Feb → Jul 2026 | coronary atherosclerosis | Beijing Inno Medicine Co., Ltd. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07311330 Comparator | Feb → Oct 2026 expected | atherosclerotic cardiovascular disease, erectile dysfunction | Beijing Inno Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YN001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05635084 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05635084 ↗ |